Magnani H - Search Results

1

Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.

Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN; Australian HIT Study Group. Chong BH, et al. Among authors: magnani h. Thromb Haemost. 2001 Nov;86(5):1170-5. Thromb Haemost. 2001. PMID: 11816702 Clinical Trial.

2

Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.

Magnani HN, Gallus A. Magnani HN, et al. Thromb Haemost. 2006 Jun;95(6):967-81. doi: 10.1160/TH05-07-0489. Thromb Haemost. 2006. PMID: 16732376 Review.

3

Orgaran in heparin-induced thrombocytopenia.

Chong BH, Magnani HN. Chong BH, et al. Among authors: magnani hn. Haemostasis. 1992;22(2):85-91. doi: 10.1159/000216299. Haemostasis. 1992. PMID: 1379968 Clinical Trial.

4

The influence of Org 10172, an antithrombotic heparinoid, on urinary blood loss after transurethral prostatectomy.

Gallus A, Murphy W, Nacey J, Morris M, Sutherland P, Marshall V, Magnani H. Gallus A, et al. Among authors: magnani h. Thromb Res. 1989 Oct 15;56(2):229-38. doi: 10.1016/0049-3848(89)90165-5. Thromb Res. 1989. PMID: 2482549 Clinical Trial.

5

Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group.

Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, Bucknall T, Stevens J, Porteous F. Gallus A, et al. Among authors: magnani h. Thromb Haemost. 1993 Oct 18;70(4):562-7. Thromb Haemost. 1993. PMID: 7509509 Clinical Trial.

6

Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis.

Cade JF, Wood M, Magnani HN, Westlake GW. Cade JF, et al. Among authors: magnani hn. Thromb Res. 1987 Mar 1;45(5):497-503. doi: 10.1016/0049-3848(87)90312-4. Thromb Res. 1987. PMID: 3590088 Clinical Trial.

7

Treatment of 51 pregnancies with danaparoid because of heparin intolerance.

Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Lindhoff-Last E, et al. Among authors: magnani hn. Thromb Haemost. 2005 Jan;93(1):63-9. doi: 10.1160/TH04-06-0345. Thromb Haemost. 2005. PMID: 15630492

8

Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172).

Magnani HN. Magnani HN. Thromb Haemost. 1993 Oct 18;70(4):554-61. Thromb Haemost. 1993. PMID: 7509508

9

Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.

Lubenow N, Warkentin TE, Greinacher A, Wessel A, Sloane DA, Krahn EL, Magnani HN. Lubenow N, et al. Among authors: magnani hn. Thromb Res. 2006;117(5):507-15. doi: 10.1016/j.thromres.2005.04.011. Thromb Res. 2006. PMID: 15907979

10

Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid.

Hoek JA, Nurmohamed MT, Hamelynck KJ, Marti RK, Knipscheer HC, ten Cate H, Büller HR, Magnani HN, ten Cate JW. Hoek JA, et al. Among authors: magnani hn. Thromb Haemost. 1992 Jan 23;67(1):28-32. Thromb Haemost. 1992. PMID: 1615479 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page